Immunome Q3 net loss widens, expects current cash to fund operations into 2027

Reuters

11/07

Immunome Q3 net loss widens, expects current cash to fund operations into 2027

Overview

Immunome reports Q3 net loss of $57.5 mln,
Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027
Research and development expenses for Q3 were $49.2 mln

Outlook

Varegacestat: Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025
Immunome expects current cash to fund operations into 2027

Result Drivers

R&D INVESTMENT - Significant investment in R&D with expenses totaling $49.2 mln for Q3
General and administrative expenses- General and administrative expenses for the quarter ended September 30, 2025 were $10.9 million

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$57.46 mln
Q3 Income From Operations		-$60.14 mln
Q3 Operating Expenses		$60.14 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunome Inc is $23.50, about 34.7% above its November 5 closing price of $15.35

Press Release: ID:nBw2ZyRqwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581046691"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581046691\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581046691?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581046691","market":"fut","top_or_hot":-1,"title":"Immunome Q3 net loss widens, expects current cash to fund operations into 2027","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immunome Q3 net loss widens, expects current cash to fund operations into 2027</title></head><body><p><span>Overview</span></p><ul><li><p>Immunome reports Q3 net loss of $57.5 mln, </p></li><li><p>Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027</p></li><li><p>Research and development expenses for Q3 were $49.2 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Varegacestat<span>: </span>Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025</p></li><li><p>Immunome expects current cash to fund operations into 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D INVESTMENT - Significant investment in R&amp;D with expenses totaling $49.2 mln for Q3</p></li><li><p>General and administrative expenses- General and administrative expenses for the quarter ended September 30, 2025 were $10.9 million</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$57.46 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$60.14 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$60.14 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Immunome Inc is $23.50, about 34.7% above its November 5 closing price of $15.35</p></li></ul><p>Press Release: <span>ID:nBw2ZyRqwa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunome Q3 net loss widens, expects current cash to fund operations into 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunome Q3 net loss widens, expects current cash to fund operations into 2027\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 06:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immunome Q3 net loss widens, expects current cash to fund operations into 2027</title></head><body><p><span>Overview</span></p><ul><li><p>Immunome reports Q3 net loss of $57.5 mln, </p></li><li><p>Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027</p></li><li><p>Research and development expenses for Q3 were $49.2 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>Varegacestat<span>: </span>Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025</p></li><li><p>Immunome expects current cash to fund operations into 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D INVESTMENT - Significant investment in R&amp;D with expenses totaling $49.2 mln for Q3</p></li><li><p>General and administrative expenses- General and administrative expenses for the quarter ended September 30, 2025 were $10.9 million</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$57.46 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$60.14 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$60.14 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Immunome Inc is $23.50, about 34.7% above its November 5 closing price of $15.35</p></li></ul><p>Press Release: <span>ID:nBw2ZyRqwa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMNM","symbol_name":"Immunome Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1K9:1","article_id":"2581046691","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581046691","pubTimestamp":1762466624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunome Q3 net loss widens, expects current cash to fund operations into 2027OverviewImmunome reports Q3 net loss of $57.5 mln, Company holds $272.6 mln in cash as of September 30, 2025, funding oper","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMNM":"Immunome Inc.","BK4139":"生物科技","BK4563":"昨日强势股"},"translate_title":"Immunome第三季度净亏损扩大，预计当前现金将为2027年的运营提供资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMNM":0.9},"content_text":"Immunome Q3 net loss widens, expects current cash to fund operations into 2027OverviewImmunome reports Q3 net loss of $57.5 mln, Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027Research and development expenses for Q3 were $49.2 mlnOutlookVaregacestat: Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025Immunome expects current cash to fund operations into 2027Result DriversR&D INVESTMENT - Significant investment in R&D with expenses totaling $49.2 mln for Q3General and administrative expenses- General and administrative expenses for the quarter ended September 30, 2025 were $10.9 millionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$57.46 mlnQ3 Income From Operations-$60.14 mlnQ3 Operating Expenses$60.14 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Immunome Inc is $23.50, about 34.7% above its November 5 closing price of $15.35Press Release: ID:nBw2ZyRqwaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}